Regulatable AAV Vector Gene Switch System
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy using adeno-associated virus (AAV) vectors is irreversible and lacks external control over transgene expression, leading to potential side effects and inefficiencies, particularly in the case of neurotrophic factor delivery for diseases like Parkinson's, where leaky expression and lack of regulatory mechanisms hinder therapeutic efficacy.
Innovation Solution
Development of an AAV vector system with a single vector genome containing a regulator protein expression cassette and a therapeutic molecule expression cassette arranged in a tail-to-head configuration, utilizing a gene switch system activated by an activator molecule like mifepristone to control the expression of neurotrophic factors such as GDNF, ensuring minimal background expression and substantial induction upon activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a constitutive promoter is used to drive therapeutic gene expression, then continuous therapeutic effect is achieved, but irreversible expression and potential side effects occur
Solution Approach 1:
The patent transforms the static, irreversible gene expression system into a dynamic, regulatable system by introducing the GeneSwitch fusion protein that can respond to external signals (mifepristone). The therapeutic gene expression becomes dynamically controllable - turning on when needed and turning off when not needed, thereby maintaining reliability while eliminating harmful uncontrolled expression.
Solution Approach 2:
The patent introduces mifepristone as an intermediary small molecule that mediates between the external environment and the therapeutic gene expression system. The GeneSwitch fusion protein acts as another intermediary that translates the presence/absence of mifepristone into controlled transcriptional activation, providing a controllable interface between external control and internal gene expression.
2Adaptability or versatility
If a two-vector system is used to achieve regulated expression, then flexibility in adjusting expression ratios is improved, but device complexity and clinical approval difficulty increase
Solution Approach 1:
The patent merges the regulatory elements (GeneSwitch fusion protein expression cassette) and the therapeutic element (therapeutic gene under minimal promoter) into a single integrated AAV vector. This consolidation maintains the regulatable expression capability while simplifying the overall system architecture, making it more suitable for clinical translation by reducing manufacturing and regulatory complexity.
Solution Approach 2:
The single AAV vector design incorporates multiple functions within one construct: it simultaneously provides the regulatory mechanism (GeneSwitch), the minimal promoter, and the therapeutic gene expression capability. This multi-functional integration eliminates the need for separate vectors while preserving the ability to regulate expression levels through mifepristone administration.
3Duration of action of stationary object
If gene therapy is designed to be irreversible, then long-term therapeutic effect is achieved, but inability to shut off expression in case of side effects occurs
Solution Approach 1:
The patent implements a feedback control mechanism where therapeutic gene expression is continuously monitored and regulated by the presence or absence of mifepristone in the system. The GeneSwitch fusion protein senses the mifepristone signal and adjusts transcriptional activation accordingly, creating a closed-loop system that maintains appropriate expression levels while allowing shutdown when needed, thus achieving both long-term efficacy and safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables regulated and controlled expression of therapeutic molecules, reducing side effects and improving therapeutic outcomes by maintaining low background levels of the therapeutic agent until activated, thereby enhancing the safety and efficacy of gene therapy for neurodegenerative diseases.
Implementation Method 1
utilizing a gene switch system activated by an activator molecule like mifepristone to control the expression of neurotrophic factors such as GDNF
Data Source
AI summary
The present invention relates to regulatable adeno-associated virus (AAV) vectors as well as to their use in gene therapy. It further relates to corresponding nucleic acid molecules, host cells, non-human transgenic animals, pharmaceutical compositions and kits.